| Income statement (USD) | Q2 2025 ended Jun 30, 2025 | Q2 2025 ended Mar 31, 2025 | Q2 2025 ended Jun 30, 2024 | Q2 2025 ended Mar 31, 2024 | Q2 2023 ended Jun 30, 2023 | Q2 2023 ended Mar 31, 2023 | Q2 2022 ended Jun 30, 2022 | Q2 2022 ended Mar 31, 2022 |
|---|---|---|---|---|---|---|---|---|
| Research and development | 234.5K | 339.3K | 1.88M | 5.75M | ||||
| Interest expense | 334 | 437 | 93 | 7.6K | ||||
| Net income | -1.84M | -1.47M | 12.88M | -3.09M | -2.68M | -2.41M | -7.22M | -5.82M |
From Addex Therapeutics Ltd.'s 10-K and 10-Q filings with the SEC. Fourth quarters, and quarters where the company only reported year-to-date totals, are worked out by subtracting the earlier quarters. Fiscal years are the company's own, so they may not match the calendar. A blank cell means the company did not report that line. New to this? Read income statement or reading a 10-K.
Revenue, earnings, margins and balance sheet trends drawn by TradingView from its own data, so figures can differ slightly from the SEC table above.